Healthcare Sales & Marketing Network News: HIZENTRA

Searching News Database: HIZENTRA

HSMN NewsFeed - 9 Dec 2019
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 16 Mar 2018
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Feb 2015
FDA Approves New Dosing Option for CSL Behring's Hizentra(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Oct 2012
Study Supports Efficacy, Safety of Hizentra(R) in Japanese Patients with Primary Immunodeficiency Disease
Biopharmaceuticals

HSMN NewsFeed - 7 Oct 2010
Data Support Hizentra(R) Efficacy, Safety After Dose-Equivalent Switch in Adult and Pediatric Patients with Primary Immunodeficiency
Biopharmaceuticals

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.